OncoMatch/Clinical Trials/NCT07335497
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Is NCT07335497 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CR-001 for locally advanced / metastatic solid tumors.
Treatment: CR-001 — The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Required: Stage III, IV
locally advanced or metastatic tumor types
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: local standard of care therapies
progressing from, intolerant to, or ineligible for (due to unavailability or contraindication) local standard of care therapies
Lab requirements
Blood counts
adequate hematologic reserve
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate organ function and hematologic reserve based on laboratory parameters
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clinical Study Site · Denver, Colorado
- Clinical Study Site · Orlando, Florida
- Clinical Study Site · Sarasota, Florida
- Clinical Study Site · Nashville, Tennessee
- Clinical Study Site · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify